Evaluation of CD38 as target for immunotherapy in multiple myeloma.
Vooijs
W C
WC
Schuurman
H J
HJ
Bast
E J
EJ
de Gast
G C
GC
D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology*; D016465:Bone Marrow Purging; D003114:Colony-Forming Units Assay; D003429:Cross Reactions; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D000922:Immunotoxins / Q000009:adverse effects* / Q000627:therapeutic use; D008562:Membrane Glycoproteins; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology; D009928:Organ Specificity; D012276:Ricin / Q000009:adverse effects* / Q000627:therapeutic use; D014410:Tumor Stem Cell Assay
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000943:Antigens, Differentiation; D000951:Antigens, Neoplasm; D000922:Immunotoxins; D008562:Membrane Glycoproteins; D012276:Ricin; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1